These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16631461)

  • 41. Can chemotherapy alter the course of prostate cancer?
    Haas NB
    Semin Urol Oncol; 2001 Aug; 19(3):212-21. PubMed ID: 11561989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy in the treatment of prostate cancer--is there a role?
    Arianayagam M; Chang J; Rashid P
    Aust Fam Physician; 2007 Sep; 36(9):737-9. PubMed ID: 17885709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
    Culine S; Droz JP
    Ann Oncol; 2000 Dec; 11(12):1523-30. PubMed ID: 11205458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
    Eisenberger MA; Antonarakis ES
    Urol Clin North Am; 2012 Nov; 39(4):573-81. PubMed ID: 23084532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
    Sonpavde G; Sternberg CN
    Int J Urol; 2010 Mar; 17(3):228-40. PubMed ID: 20088874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prostate cancer: future strategies for chemotherapy management].
    Fizazi K
    Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S77-9. PubMed ID: 18297905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
    Brandi G; de Rosa F; Danesi R; Montini GC; Biasco G
    Eur Urol; 2008 Oct; 54(4):938-41. PubMed ID: 18657896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
    DeGrendele H
    Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878
    [No Abstract]   [Full Text] [Related]  

  • 51. Chemotherapy of prostate cancer: present and future.
    Trump D; Lau YK
    Curr Urol Rep; 2003 Jun; 4(3):229-32. PubMed ID: 12756087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Chemotherapy for prostate cancer].
    Rauchenwald M; De Santis M; Fink E; Höltl W; Kramer G; Marei IC; Neumann HJ; Reissigl A; Schmeller N; Stackl W; Hobisch A; Krainer M
    Wien Klin Wochenschr; 2008; 120(13-14):440-9. PubMed ID: 18726672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.
    Armstrong AJ; Carducci MA
    Curr Oncol Rep; 2005 May; 7(3):220-7. PubMed ID: 15847714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy for prostate cancer: finally an advance!
    Gulley J; Dahut WL
    Am J Ther; 2004; 11(4):288-94. PubMed ID: 15266221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.
    Heidenreich A; von Knobloch R; Hofmann R
    Eur Urol; 2001 Feb; 39(2):121-30. PubMed ID: 11223670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The medical management of prostate cancer: a multidisciplinary team approach.
    Sternberg CN; Krainer M; Oh WK; Bracarda S; Bellmunt J; Ozen H; Zlotta A; Beer TM; Oudard S; Rauchenwald M; Skoneczna I; Borner MM; Fitzpatrick JM
    BJU Int; 2007 Jan; 99(1):22-7. PubMed ID: 16956362
    [No Abstract]   [Full Text] [Related]  

  • 57. Chemotherapy agents and timing of chemotherapy in prostate cancer management.
    Donohue KM; Petrylak DP
    Curr Urol Rep; 2005 May; 6(3):224-7. PubMed ID: 15869727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.
    Di Lorenzo G; Autorino R
    Eur Urol; 2007 Aug; 52(2):613-4. PubMed ID: 17416455
    [No Abstract]   [Full Text] [Related]  

  • 59. A population-based study of prostate cancer chemotherapy.
    Harris V; Lloyd K; Forsey S; Rogers P; Roche M; Parker C
    Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):706-8. PubMed ID: 21602036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Upfront Chemotherapy for Metastatic Prostate Cancer.
    Lam ET; Flaig TW
    Oncology (Williston Park); 2015 Dec; 29(12):956-62. PubMed ID: 26676900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.